48288 Federal Register / Vol. 72, No. 163 / Thursday, August 23, 2007 / Notices 

measurements of a sequence common to 

several targets. 

The method’s software design allows 

for large (>10,000) target sets and large 

probe set sizes (2->1,000,000). While 

current selection criteria involve a time 

consuming iterative and manual 

process, the present invention allows for 

the identification of a quantitatively 

optimized probe set which balances 

probe performance criteria and 

simultaneously optimizes the sensitivity 

and specificity of the assay for a given 

set of targets. 

Applications: The invention has 

applications in the design of various 

important assays, such as those based 

on microarrays, multiplexed PCR and 

SPR, targeted protein fragment 

detection, or any sequence-specific 

binding and detection. It has application 

where the number of probes to be used 

in an assay is too large for manual 

design and review. 

Inventors: Eric Billings and Kevin E. 

Brown (NHLBI). 

Patent Status: U.S. Provisional 

Application No. 60/871,447 filed 21 Dec 

2006, entitled ‘‘Probe Set Global 

Optimization’’ (HHS Reference E–332–

2005/0–US–01). 

Development Status: The technology 

is ready to be applied and validated in 

many different areas for research and 

diagnostic purposes. 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Cristina 

Thalhammer-Reyero, Ph.D., M.B.A.; 

301/435–4507; thalhamc@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Heart, Lung and Blood 

Institute, Computational Biophysics 

Laboratory is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, utilize or 

commercialize a method for optimizing 

sequence-based assays. Please contact 

Dr. Eric Billings, at (301) 496–6520 or 

via e-mail at billings@helix.nih.gov for 

more information. 

Dated: August 16, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–16644 Filed 8–22–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Advisory Eye Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Eye Council. 

Date: September 27, 2007. 

Closed: 8:30 a.m. to 10:30 a.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, 5635 

Fishers Lane, Terrace Level Conference 

Center, Bethesda, MD 20982. 

Open: 10:30 a.m. to Adjournment. 

Agenda: Following opening remarks by the 

Director, NEI there will be presentations by 

the staff of the Institute and discussions 

concerning Institute programs. 

Place: National Institutes of Health, 5635 

Fishers Lane, Terrace Level Conference 

Center, Bethesda, MD 20892. 

Contact Person: Lore Anne McNicol, PhD, 

Director, Division of Extramural Research, 

National Eye Institute, National Institutes of 

Health, Bethesda, MD 20892, (301) 451–2020. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institutes’s/Center’s home page: http:// 

www.nei.nih.gov, where an agenda and any 

additional information for the meeting will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: August 14, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–4100 Filed 8–21–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Supplementary Risk Assessments and 

Site Suitability Analyses for the 

National Emerging Infectious Disease 

Laboratory, Boston University Medical 

Center 

ACTION: Availability of Supplementary 

Risk Assessments and Site Suitability 

Analyses for the National Emerging 

Infectious Disease Laboratory, Boston 

University Medical Center; notice of 

hearing. 

SUMMARY: The National Institutes of 

Health (NIH) has placed in the docket 

for public review and comment the 

Supplementary Risk Assessments and 

Site Suitability Analyses for the 

National Emerging Infectious Disease 

Laboratory, Boston University Medical 

Center, which address additional 

concerns of the local community 

regarding possible impacts of the 

National Emerging Infectious Diseases 

Laboratory, Boston University Medical 

Center. The purpose of the 

Supplementary Risk Assessments and 

Site Suitability Analyses for the 

National Emerging Infectious Disease 

Laboratory was alternative site analysis 

and risk assessment that investigated 

potential infectious disease threats that 

may be posed to the public should an 

exotic infectious agent be released into 

the community through an infected 

laboratory worker, laboratory accident, 

or other mishap. 

DATES: Comments on the 

Supplementary Risk Assessments and 

Site Suitability Analyses for the 

National Emerging Infectious Disease 

Laboratory must be received by 

Monday, November 12th. A public 

hearing will be held on Thursday, 

September 20, 2007, from 7–9 p.m. at 

Faneuil Hall, Dock Square, Boston, MA 

02109. 

ADDRESSES: Comments should be sent to 

Valerie Nottingham, Division of 

Environmental Protection, National 

Institutes of Health, 9000 Rockville 

Pike, Building 13, Room 2S11, 

Bethesda, MD 20892, MSC 5746. E-mail 

comments should be sent to 

nihnepa@mail.nih.gov. Comments sent 

by e-mail must be received by 11:59 


ebenthall on PRODPC61 with NOTICES